Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

NCT07146022 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

552

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgenetic Alopecia (AGA)
Androgenetic Alopecia
AGA
Female Androgenetic Alopecia
Hair Loss

Interventions

DRUG: VDPHL01 QD
DRUG: Placebo
DRUG: VDPHL01 BID
DRUG: Placebo

Sponsor

Veradermics, Inc.